Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
BACKGROUND
The optimal duration of therapy for women with platinum-resistant ovarian cancer who respond to second-line treatment programs remains undefined.


METHODS
A patient with well-documented platinum-resistant ovarian cancer who responded to single-agent paclitaxel (175 mg/m2 over 3 hours q 28-35 days) was continued on this program for a total of 15 cycles delivered over a period of 16 months. The patient has subsequently remained without evidence of disease recurrence >7 years following discontinuation of this treatment regimen.


CONCLUSIONS
The prolonged administration of paclitaxel, a highly cycle-specific cytotoxic agent, is a rational management option in patients with platinum-resistant ovarian cancer who exhibit evidence of a response to therapy and who do not experience excessive treatment-associated toxicity (e.g., grade 2-3 peripheral neuropathy).
Markman
Maurie
M
Department of Medical Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. mmarkman@mdanderson.org
Webster
Kenneth
K
Kulp
Barbara
B
Peterson
Gertrude
G
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D017239:Paclitaxel; D002945:Cisplatin